Johnson & Johnson

Johnson & Johnson <JNJ.N> said on Friday it is recalling around 33,000 bottles of baby powder in the United States after U.S. health regulators found trace amounts of asbestos in samples taken from a bottle purchased online.

The U.S. Food & Drug Administration said on Friday that it found that a sample from one lot of Johnson & Johnson's baby powder contained chrysotile fibers, a type of asbestos, confirming test results the company disclosed earlier on Friday.

The U.S. Food & Drug Administration said on Friday that it found that a sample from one lot of Johnson & Johnson's baby powder contained chrysotile fibers, a type of asbestos, confirming test results the company disclosed earlier on Friday.

* Indexes down: Dow 0.67%, S&P 500 0.43%, Nasdaq 0.97% (Updates to early afternoon)

* Indexes off: Dow 0.28%, S&P 500 0.15%, Nasdaq 0.50% (Adds comments, updates market action)

U.S. stocks opened slightly lower on Friday, weighed down by Johnson & Johnson, while upbeat earnings reports limited losses and calmed nerves about the global economy after China expanded at its weakest pace in almost 30 years.

Johnson & Johnson said on Friday that it would recall a single lot of its baby powder in the United States after the Food and Drug Administration found trace amounts of asbestos in samples taken from a bottle purchased online.

Johnson & Johnson's nasal spray for depression won recommendation for approval from a European Medicines Agency (EMA) panel, the regulatory body said on Friday.

Johnson & Johnson has agreed to pay nearly $117 million to resolve allegations that it deceptively marketed transvaginal surgical mesh devices, U.S. state attorneys general said on Thursday.

U.S. state attorneys general said on Thursday that Johnson & Johnson and its unit had agreed to pay nearly $117 million to settle litigation over deceptive marketing of the company's transvaginal surgical mesh devices.

A Missouri appeals court overturned a $110 million verdict against Johnson & Johnson <JNJ.N> in a lawsuit by a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

Johnson & Johnson <JNJ.N> raised its full-year earnings forecast on Tuesday as it reported higher third-quarter sales of psoriasis treatment Stelara and cancer drug Imbruvica while attempting to alleviate investor concerns over mounting legal challenges.

U.S. stocks opened higher on Tuesday, as strong earnings reports from JPMorgan Chase, UnitedHealth and Johnson & Johnson allayed concerns about the fallout from a prolonged U.S.-China trade war on corporate America.

U.S. stock index futures rose on Tuesday, as the third-quarter earnings season got off to an upbeat start with robust reports from JPMorgan Chase, UnitedHealth and Johnson & Johnson.

Johnson & Johnson on Tuesday posted a 22.9% rise in third-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.

A jury award that hit Johnson & Johnson <JNJ.N> with $8 billion in punitive damages for a case involving its anti-psychotic drug Risperdal highlights the risks of the drugmaker's all-or-nothing legal strategy, several legal experts told Reuters on Wednesday.

Shares of Johnson & Johnson dipped 2% on Wednesday after a jury awarded $8 billion in punitive damages to a man who accused the drugmaker of failing to warn that young men using its antipsychotic drug Risperdal could grow breasts.

Johnson & Johnson must pay $8 billion in punitive damages to a man who previously won $680,000 over his claims that it failed to warn that young men using its antipsychotic drug Risperdal could grow breasts, a Philadelphia jury said on Tuesday.

Oklahoma's attorney general has moved to appeal a judge's ruling holding that state had only established it was entitled to just $572 million of the $17 billion it requested on its claims that Johnson & Johnson fueled the opioid epidemic through deceptive painkiller marketing...